Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.

about

Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.

Item

http://www.wikidata.org/entity/Q40283574

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.

@en

type

Item

label

Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.

@en

prefLabel

Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.

@en

P1476

Potential role of tyrosine kinase inhibitors during primary HIV-1 infection

@en

P2093

José M Miró

http://www.w3.org/2001/XMLSchema#string

Juan Ambrosioni

http://www.w3.org/2001/XMLSchema#string

P2860

Immunological off-target effects of imatinib.

Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells

Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study

Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel

Defective proviruses rapidly accumulate during acute HIV-1 infection

Philadelphia chromosome-positive acute lymphoblastic leukemia with extramedullary and meningeal relapse after allogeneic hematopoietic stem cell transplantation that was successfully treated with dasatinib.

Update on antiretroviral treatment during primary HIV infection.

Chronic myeloid leukemia: First-line drug of choice.

P304

421-423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/14787210.2017.1308823

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

José Alcamí

Mayte T. Coiras

P577

2017-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28322065

http://www.w3.org/2001/XMLSchema#string